Bifunctional EGFR Compounds for Resistant Mutation Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EGFR-targeting PROTACs fail to effectively degrade all major EGFR mutations, such as Del19, L858R, Del19/T790M, L858R/T790M, and L858R/T790M/C797S, in non-small cell lung cancer, necessitating the development of novel compounds that can overcome drug resistance mediated by these mutants.
Innovation Solution
Conjugating EGFR inhibitor moieties with E3 ligase ligands to form bifunctional compounds that recruit targeted proteins to E3 ubiquitin ligase for degradation, utilizing novel compounds of specific structures to target and degrade EGFR mutant proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGFR-targeting PROTACs are used, then some EGFR mutations can be targeted, but they fail to effectively degrade all major EGFR mutations (Del19, L858R, Del19/T790M, L858R/T790M, L858R/T790M/C797S)
Solution Approach 1:
The patent designs a universal PROTAC compound structure that can bind to multiple EGFR mutation types (Del19, L858R, T790M, C797S) through a single molecule, achieving multi-functional degradation coverage across all major EGFR mutations rather than requiring separate PROTACs for each mutation type
Solution Approach 2:
The patent modifies the chemical structure parameters of the PROTAC compound, specifically adjusting the EGFR inhibitor moiety and linker regions to optimize binding affinity and degradation efficacy across different EGFR mutation substrates, enabling effective degradation of previously resistant mutants
2Reliability
If traditional EGFR inhibitors are used, then EGFR enzymatic activity is inhibited, but drug resistance develops in patients after average of one year treatment
Solution Approach 1:
The patent extracts the target protein (EGFR) from the cell and eliminates it completely through proteasomal degradation via PROTAC mechanism, rather than merely inhibiting its enzymatic activity, thereby achieving durable response by removing the source of resistance mutations
Solution Approach 2:
Instead of inhibiting EGFR activity to achieve therapeutic effect, the patent inverts the approach by using PROTACs to degrade the EGFR protein itself, including resistant mutants, thereby achieving both immediate efficacy and long-term durability by eliminating the target rather than suppressing its function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel bifunctional compounds effectively degrade various EGFR mutations, providing a potential therapeutic strategy to overcome drug resistance in non-small cell lung cancer.
Implementation Method 1
recruitment of the E3 ligase to the specific unwanted proteins results in ubiquitination and subsequent degradation of the target protein by the proteasome
Implementation Method 2
subsequent degradation of the target protein by the proteasome
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.